Los Angeles Capital Management’s Sana Biotechnology SANA Stock Holding History

Los Angeles Capital Management’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$675K	Buy	193,283 +118,456	+158%	+$382K	﹤0.01%	834
2026 Q1	$216K	Buy	74,827 +73,333	+4,909%	+$289K	﹤0.01%	1121
2025 Q4	$7.32K	Sell	1,494 -21,716	-94%	-$97.2K	﹤0.01%	2189
2025 Q3	$82.4K	Sell	23,210 -45	-0.2%	-$163	﹤0.01%	1323
2025 Q2	$63.5K	Buy	+23,255	New	+$48K	﹤0.01%	1286
2024 Q2	–	Sell	-70,245	Closed	-$702K	–	1270
2024 Q1	$702K	Sell	70,245 -64,393	-48%	-$482K	﹤0.01%	789
2023 Q4	$549K	Sell	134,638 -1,043	-0.8%	-$3.84K	﹤0.01%	839
2023 Q3	$525K	Buy	135,681 +1,043	+0.8%	+$5.61K	﹤0.01%	813
2023 Q2	$802K	Sell	134,638 -3,700	-3%	-$21.3K	﹤0.01%	707
2023 Q1	$452K	Sell	138,338 -2,981	-2%	-$11.9K	﹤0.01%	886
2022 Q4	$558K	Hold	141,319	–	–	﹤0.01%	862
2022 Q3	$848K	Sell	141,319 -16,170	-10%	-$117K	﹤0.01%	757
2022 Q2	$1.01M	Sell	157,489 -147,177	-48%	-$938K	0.01%	720
2022 Q1	$2.52M	Buy	+304,666	New	+$2.46M	0.01%	476

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Los Angeles Capital Management's SANA Position: Q2 2026 in Review

Los Angeles Capital Management increased its Sana Biotechnology (SANA) stake by 158% in Q2 2026, buying an estimated $382K and bringing the position to 193,283 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #834.

Los Angeles Capital Management first reported a position in SANA in Q1 2022 and has held it in 14 quarters since. The position peaked at $2.52M in Q1 2022. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

Los Angeles Capital Management held 193,283 shares of Sana Biotechnology worth $675K as of Q2 2026.
Los Angeles Capital Management bought 118,456 Sana Biotechnology shares in Q2 2026, an estimated $382K.
Sana Biotechnology made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #834 holding.
Los Angeles Capital Management first reported a position in Sana Biotechnology in Q1 2022 and has held it in 14 quarters since.
Los Angeles Capital Management's Sana Biotechnology position peaked at $2.52M in Q1 2022.
211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.